NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET
NLS 将于美国东部时间 2023 年 7 月 6 日星期四上午 11:00 对其活动进行网络直播
ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update. The webcast will now take place on Thursday, July 6, 2023, at 11:00AM ET. Members of the NLS Leadership Team will discuss the global strategic research and development progress and platform, including:
瑞士苏黎世/ACCESSWIRE /2023 年 6 月 30 日/ NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP）（纳斯达克股票代码：NLSP）（纳斯达克股票代码：NLSPW）（“NLS” 或 “公司”）是一家瑞士临床阶段的生物制药公司，专注于为罕见和复杂的中枢神经系统疾病患者发现和开发创新疗法，该公司今天宣布，由于重要进展影响了公司更新的时机，它将推迟原定于今天举行的网络直播。网络直播现在将在美国东部时间2023年7月6日星期四上午11点举行。NLS领导团队的成员将讨论全球战略研发进展和平台，包括：
- Feedback from the SLEEP 2023 APSS Conference
- Initiation of the Phase 3 program AMAZE for Mazindol ER
- Pipeline Goals for 2023/2024
- Key Financials
- Funding Strategy Update
- Corporate Development
- 来自 SLEEP 2023 APSS 会议的反馈
- 为 Mazindol ER 启动第 3 阶段计划 AMAZE
- 2023/2024 年计划目标
- 主要财务状况
- 融资策略更新
- 企业发展
Webcast Information
网络直播信息
The event will be held July 6, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website found here or at the SummitCast event page found here. A replay will be available on NLS' website within 48 hours after the event.
该活动将于美国东部时间2023年7月6日上午11点举行，并将包括公司网站投资者部分的视频直播，也可以在这里找到的SummitCast活动页面。活动结束后48小时内将在NLS的网站上提供重播。
About NLS Pharmaceutics Ltd.
关于 NLS 制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP）是一家处于开发阶段的全球生物制药公司，与世界一流的合作伙伴和国际知名的科学家网络合作，专注于为医疗需求未得到满足的罕见和复杂中枢神经系统疾病患者发现和开发创新疗法。NLS总部位于瑞士，成立于2015年，由一支经验丰富的管理团队领导，他们在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
玛丽安·兰伯森（投资者和媒体）
NLS 制药有限公司
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
来源： NLS 制药股份有限公司